Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) traded up 5.3% on Wednesday . The stock traded as high as $13.10 and last traded at $12.95. 1,039,564 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 2,049,715 shares. The stock had previously closed at $12.30.

Several analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, August 8th. B. Riley boosted their price target on shares of Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and issued a $20.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, August 8th. Chardan Capital reissued a “buy” rating and issued a $17.50 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 13th. Finally, William Blair reissued an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $21.45.

The company has a market cap of $1.07 billion, a P/E ratio of -27.55 and a beta of 2.07. The company has a current ratio of 8.69, a quick ratio of 8.69 and a debt-to-equity ratio of 0.02.

In other news, CFO Kenneth Allen Myszkowski sold 45,000 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $19.34, for a total transaction of $870,300.00. Following the completion of the transaction, the chief financial officer now directly owns 335,815 shares of the company’s stock, valued at $6,494,662.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $14.45, for a total transaction of $1,445,000.00. Following the transaction, the chief executive officer now directly owns 1,868,789 shares of the company’s stock, valued at $27,004,001.05. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 522,471 shares of company stock valued at $7,638,974. Insiders own 4.60% of the company’s stock.

Large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $100,000. Great West Life Assurance Co. Can purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $106,000. Stratos Wealth Partners LTD. purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at about $123,000. Meeder Asset Management Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at about $129,000. Finally, Macquarie Group Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $151,000. 64.23% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dailypolitical.com/2018/11/21/arrowhead-pharmaceuticals-arwr-trading-5-3-higher.html.

Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Further Reading: Are all No-Load Funds Equal?

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.